Geriatric Depression Scale

From WikiMD's WELLNESSPEDIA

The Geriatric Depression Scale (GDS) is a psychological assessment tool designed to measure depression in older adults. The scale was first developed by J.A. Yesavage and colleagues in 1982, and has since been used extensively in both clinical and research settings.

Overview[edit]

The GDS is a self-report measure that consists of 30 items. Each item is a yes/no question related to the individual's feelings over the past week. The scale is specifically designed to avoid focusing on somatic symptoms, given that these can often be attributed to physical health problems common in older adults. Instead, the GDS focuses on cognitive and affective symptoms of depression.

Scoring and Interpretation[edit]

Scores on the GDS range from 0 to 30, with higher scores indicating greater levels of depressive symptoms. A score of 0-9 is considered normal, 10-19 indicates mild depression, and 20-30 indicates severe depression. It is important to note that the GDS is a screening tool and not a diagnostic tool. Therefore, a high score should be followed up with a comprehensive clinical assessment to confirm a diagnosis of depression.

Validity and Reliability[edit]

The GDS has been found to have good psychometric properties, including high internal consistency and good test-retest reliability. It has also been validated against other measures of depression, such as the Hamilton Depression Rating Scale.

Limitations[edit]

While the GDS is a valuable tool for identifying depression in older adults, it does have some limitations. For example, it may not be as effective in individuals with cognitive impairment or those with a high level of physical illness. Additionally, it does not assess for suicidal ideation, which is an important component of depression.

See Also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.